Why Liquidia Stock Rocked the Market Today
Key Points
The biotech posted preliminary sales results for Yutrepia.
This is its latest commercialized product, approved by the FDA in May 2025.
- 10 stocks we like better than Liquidia ›
Biotech Liquidia (NASDAQ: LQDA) had good news to report about its latest commercialized product as the trading week came to a close. On an update about that product, Yutrepia, investors snapped up the company's shares to boost them to a nearly 13% gain on Friday.
New kid on the block
Before market open, Liquidia published preliminary sales results for Yutrepia for 2025. The drug, which is indicated for the treatment of pulmonary arterial hypertension (PAH) and pulmonary arterial hypertension with interstitial lung disease (PH-ILD), was approved by the U.S. Food and Drug Administration (FDA) for both conditions last May.
Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now, when you join Stock Advisor. See the stocks »
Image source: Getty Images.
Across that year, the company's net product sales for Yutrepia totaled roughly $148.3 million. The drug clearly had momentum, as $90.1 million of that tally was earned in the fourth quarter alone.
The product is already having a positive effect on Liquidia's finances. The company reported that it generated over $30 million in positive cash flow during that pivotal fourth quarter, which helped boost its cash and cash equivalents to around $190.7 million at the end of 2025.
In that update, Liquidia said it had major plans for the future of both Yutrepia and its leading investigational drug L606, another PAH and PH-ILD treatment.
The healthcare company wrote that it aimed to bolster "clinical programs to further differentiate Yutrepia and L606, our extended-release treprostinil formulation, across current and potential future indications."
Quite the up-and-coming treatment
If I were a Liquidia investor, I'd also be cheered by the fairly rapid progress of Yutrepia on the market. Early indications suggest that the drug is experiencing strong demand, to the point where it could potentially become a go-to medication for at least the two approved indications.
Should you buy stock in Liquidia right now?
Before you buy stock in Liquidia, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Liquidia wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $488,222!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,134,333!*
Now, it’s worth noting Stock Advisor’s total average return is 969% — a market-crushing outperformance compared to 196% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of January 9, 2026.
Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
